Uncovering the Role of Epicardial Adipose Tissue in Heart Failure With Preserved Ejection Fraction.

atrial fibrillation epicardial adipose tissue heart failure with preserved ejection fraction inflammation

Journal

JACC. Advances
ISSN: 2772-963X
Titre abrégé: JACC Adv
Pays: United States
ID NLM: 9918419284106676

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 19 05 2023
revised: 07 08 2023
accepted: 10 08 2023
medline: 28 6 2024
pubmed: 28 6 2024
entrez: 28 6 2024
Statut: epublish

Résumé

Heart failure with preserved ejection fraction (HFpEF) is the most common form of heart failure. Obesity is a modifiable risk factor of HFpEF; however, body mass index provides limited information on visceral adiposity and patients with similar anthropometrics can present variable cardiovascular risk. Epicardial adipose tissue (EAT) is the closest fat deposit to the heart and has been proposed as a biomarker of visceral adiposity. EAT may be particularly important for cardiac function, because of its location (under the pericardium) and because it acts as a metabolically active endocrine organ (which can produce both beneficial and detrimental cytokines). In this paper, the authors review the role of EAT in normal and pathologic conditions and discuss the noninvasive imaging modalities that allow its identification. This review highlights EAT implications in HFpEF and discuss new therapies that act on EAT and might also exert beneficial effects on the cardiovascular system.

Identifiants

pubmed: 38938732
doi: 10.1016/j.jacadv.2023.100657
pii: S2772-963X(23)00645-2
pmc: PMC11198699
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

100657

Informations de copyright

© 2023 The Authors.

Déclaration de conflit d'intérêts

The project that gave rise to these results received the support of a fellowship from 10.13039/100010434‘la Caixa’ Foundation (ID 100010434). The fellowship code is LCF/BQ/EU21/11890141. Dr Devesa is recipient of an Alfonso Martin Escudero grant. Dr Santos-Gallego is supported by the Robert Winn Career Development Award. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Auteurs

Sarah A Goldman (SA)

Department of Internal Medicine, Zucker School of Medicine at Hofstra Northwell, Lenox Hill Hospital New York, New York, New York, USA.

Juan Antonio Requena-Ibanez (JA)

Atherothrombosis Research Unit, Mount Sinai Heart, Icahn School of Medicine at Mount Sinai School of Medicine, New York, New York, USA.

Ana Devesa (A)

Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
BioMedical Engineering and Imaging Institute (BMEII), Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain.

Carlos G Santos-Gallego (CG)

Atherothrombosis Research Unit, Mount Sinai Heart, Icahn School of Medicine at Mount Sinai School of Medicine, New York, New York, USA.

Juan José Badimon (JJ)

Atherothrombosis Research Unit, Mount Sinai Heart, Icahn School of Medicine at Mount Sinai School of Medicine, New York, New York, USA.

Valentin Fuster (V)

Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain.

Classifications MeSH